^
    Back
    Association details:
    Biomarker:NFKBIE mutation + TMB-H
    Cancer:Melanoma
    Drug Class:PD1 inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Cancers (Basel)
    Title:

    Pre-Treatment Mutational and Transcriptomic Landscape of Responding Metastatic Melanoma Patients to Anti-PD1 Immunotherapy

    Excerpt:
    Immunotherapy, such as anti-PD1, has improved the survival of patients with metastatic melanoma....Patients that harbored NFKBIE-related gene mutations also had a higher mutational burden, decreased tumor volume with treatment, and increased progression-free survival.
    DOI:
    10.3390/cancers12071943